首页 | 本学科首页   官方微博 | 高级检索  
     

儿童呼吸道合胞病毒感染的药物治疗研究进展及其预防策略
引用本文:高微微,邹映雪. 儿童呼吸道合胞病毒感染的药物治疗研究进展及其预防策略[J]. 现代药物与临床, 2023, 38(8): 2073-2079
作者姓名:高微微  邹映雪
作者单位:天津市儿童医院/天津大学儿童医院 马场院区呼吸科, 天津 300074
基金项目:天津市医学重点学科(专科)建设项目(TJYXZDXK-040A)
摘    要:呼吸道合胞病毒是引起儿童下呼吸道感染的主要原因,目前临床主要的治疗措施为对症支持治疗,尚缺乏特异性抗病毒药物和安全有效的预防措施。近年来,多种新型药物已经进入了临床研究后阶段,部分药物已上市。综述了治疗呼吸道合胞病毒的早期和新型抗病毒药物的研究进展以及呼吸道合胞病毒主动、被动免疫预防策略,旨在提高临床医生对儿童呼吸道合胞病毒防治策略的认识。

关 键 词:早期抗病毒药物  新型抗病毒药物  呼吸道合胞病毒  主动免疫  被动免疫
收稿时间:2023-05-26

Research progress on drug therapy and prevention strategies of respiratory syncytial virus infection in children
GAO Wei-wei,ZOU Ying-xue. Research progress on drug therapy and prevention strategies of respiratory syncytial virus infection in children[J]. Drugs & Clinic, 2023, 38(8): 2073-2079
Authors:GAO Wei-wei  ZOU Ying-xue
Affiliation:Department of Respiratory, Machang District, Tianjin Children''s Hospital/Tianjin University Children''s Hospital, Tianjin 300074, China
Abstract:Respiratory syncytial virus (RSV) is the main cause of lower respiratory tract infection in infants. At present, the main clinical treatment measures for RSV were symptomatic support treatment, and there was still a lack of specific antiviral drug and safe and effective preventive measures. In recent years, many drugs have entered the post-clinical research phase, and some drugs have been on the market. This article reviews the research progress of early antiviral drug and new antiviral drug for the treatment of RSV, as well as the prevention strategies of active and passive immunity of RSV, in order to improve clinicians'' understanding of the prevention and treatment strategies of children''s RSV.
Keywords:early antiviral drug  new antiviral drug  respiratory syncytial virus  active immunity  passive immunity
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号